• HOME>
  • Investor Relations>
  • IR News>
  • Donations to the Kitasato Institute's Project for COVID-19 for Early Identification of Therapeutic Medicine for its Treatment

IR News

Mar. 31, 2020Print(PDF/85KB)CSR

Donations to the Kitasato Institute's Project for COVID-19 for Early Identification of Therapeutic Medicine for its Treatment

We at Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) would like to express our heartfelt sympathy to those who have been affected by pneumonia caused by the new coronavirus. We sincerely hope that this infection will be contained as soon as possible.

Sumitomo Dainippon Pharma announced today its decision to donate 10 million yen to the Kitasato Institute's Project for COVID-19, which was launched in March 2020 by the Kitasato Institute (Location: Minato-ku, Tokyo, Japan; Chairperson: Hirosuke Kobayashi).

This project aims to isolate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from specimens of patients affected by COVID-19, to identify clinical candidates for the treatment of this new virus infection speedily through a large-scale screening of approved pharmaceuticals and to save patients' lives.

Aspiring to contribute to global health, Sumitomo Dainippon Pharma dedicates its R&D efforts to infectious diseases area: drugs to treat infections caused by antimicrobial resistant bacteria with the Kitasato Institute, an influenza vaccine that is adaptable to antigen mutations with the National Institutes of Biomedical Innovation, Health and Nutrition, and a malaria vaccine with Ehime University and another organization.